|
See related Exjade tab information |
|
|
|
Manufacturer |
Novartis |
|
Distributor |
Zuellig |
|
Contents |
Deferasirox |
|
Indications |
Treatment of chronic Fe overload due to blood transfusions (transfusional haemosiderosis) in adult & ped patients ≥2 yr.
Click to view Exjade detailed prescribing infomation |
|
Dosage |
20-30 mg/kg body wt determined by the frequency of blood transfusion & goal of treatment. May be increased up to 40 mg/kg if inadequately controlled. Starting dose >30 mg/kg is not recommended.
Click to view Exjade detailed prescribing infomation |
|
Overdosage |
View Exjade overdosage for action to be taken in the event of an overdose. |
|
Administration |
Should be taken on an empty stomach (Take on an empty stomach at least 30 min before meals, preferably at the same time daily. Disperse the tab by stirring in 100-200 mL of water or orange juice until a fine susp is obtained. After the susp has been drunk, any residue must be resuspended in a small vol of water or orange juice & drunk. Do not chew or swallow the tab.). |
|
Contraindications |
[Click for Exjade detailed prescribing infomation] |
|
Special Precautions |
Monthly monitoring of serum creatinine, proteinuria & serum transaminases. Renal & hepatic impairment. Skin rashes, severe hypersensitivity reaction (discontinue). Annual eye/ear testing. Exjade contains lactose. Pregnancy & lactation.
Click to view Exjade detailed prescribing infomation |
|
Adverse Drug Reactions |
Nausea, vomiting, diarrhea, abdominal pain, rash, nonprogressive increase in serum creatinine & transminases, abdominal distention, constipation, dyspepsia, proteinuria, headache. Acute renal failure, hypersensitivity reactions (eg anaphylaxis & angioedema), severe skin rash, maculopathy, hepatitis, leukocytoclastic vasculitis, urticaria.
View ADR Monitoring Form |
|
Drug Interactions |
Not to be taken w/ Al-containing antacids, other Fe-chelator therapies.
View more drug interactions with Exjade |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Storage |
View Exjade storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Exjade description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Exjade mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Exjade tablet |
|
Exjade 250 mg x 4 x 7's |
 |
|
|
|
Manufacturer: |
Novartis |
|
Distributor: |
Zuellig |
|
|
|
|
|
